The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | The role of venetoclax-based combinations and novel agents in AML treatment
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the growing role of venetoclax-based combinations in the treatment of patients with transplant-eligible acute myeloid leukemia (AML). Dr Cerchione highlights promising data observed with these combinations in various trials, and further comments on the value of using measurable residual disease (MRD) as an endpoint in clinical trials. To conclude, Dr Cerchione highlights the growing use of personalized therapy in this disease setting. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
